ChronoScale Corporation Common Stock (NASDAQ:CHRN) Shares Down 6.1% – Should You Sell?

ChronoScale Corporation Common Stock (NASDAQ:CHRN)’s stock price traded down 6.1% during mid-day trading on Wednesday . The company traded as low as $19.78 and last traded at $19.78. 40,809 shares traded hands during mid-day trading, a decline of 83% from the average daily volume of 240,936 shares. The stock had previously closed at $21.06.

Analyst Ratings Changes

Separately, Weiss Ratings upgraded ChronoScale Corporation Common Stock from a “sell (d-)” rating to a “sell (d)” rating in a report on Monday, August 24th. One equities research analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, ChronoScale Corporation Common Stock has an average rating of “Reduce” and a consensus target price of $6.00.

ChronoScale Corporation Common Stock Price Performance

The company’s fifty day moving average is $21.41 and its 200 day moving average is $16.73. The company has a quick ratio of 0.51, a current ratio of 0.51 and a debt-to-equity ratio of 0.06. The stock has a market cap of $2.62 billion, a PE ratio of -3.34 and a beta of 0.98.

ChronoScale Corporation Common Stock (NASDAQ:CHRN) last announced its quarterly earnings results on Wednesday, August 19th. The company reported ($0.12) earnings per share for the quarter. ChronoScale Corporation Common Stock had a negative net margin of 135.66% and a negative return on equity of 197.81%. The business had revenue of $18.40 million for the quarter. As a group, sell-side analysts anticipate that ChronoScale Corporation Common Stock will post -0.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the stock. Geode Capital Management LLC lifted its position in ChronoScale Corporation Common Stock by 68.9% during the 4th quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock worth $218,000 after acquiring an additional 10,281 shares in the last quarter. Citadel Advisors LLC acquired a new stake in ChronoScale Corporation Common Stock in the third quarter valued at approximately $198,000. Shay Capital LLC acquired a new stake in ChronoScale Corporation Common Stock in the third quarter valued at approximately $67,000. Virtu Financial LLC acquired a new stake in ChronoScale Corporation Common Stock in the third quarter valued at approximately $57,000. Finally, Roble Belko & Company Inc raised its stake in shares of ChronoScale Corporation Common Stock by 104.5% during the first quarter. Roble Belko & Company Inc now owns 2,338 shares of the company’s stock valued at $25,000 after purchasing an additional 1,195 shares during the period. 6.42% of the stock is owned by hedge funds and other institutional investors.

ChronoScale Corporation Common Stock Company Profile

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.